Welcome!

News Feed Item

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703947/Aortic-Valve-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Aortic Valve Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aortic Valve Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Aortic Valve Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Aortic Valve Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Unaccomplished Trials of Aortic Valve Stenosis 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Aortic Valve Stenosis Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Edwards Lifesciences Corporation 30
Clinical Trial Overview of Edwards Lifesciences Corporation 30
CryoLife, Inc. 31
Clinical Trial Overview of CryoLife, Inc. 31
AstraZeneca PLC 32
Clinical Trial Overview of AstraZeneca PLC 32
Pfizer Inc. 33
Clinical Trial Overview of Pfizer Inc. 33
Merck & Co., Inc. 34
Clinical Trial Overview of Merck & Co., Inc. 34
Direct Flow Medical, Inc. 35
Clinical Trial Overview of Direct Flow Medical, Inc. 35
Cerenis Therapeutics SA 36
Clinical Trial Overview of Cerenis Therapeutics SA 36
A. Menarini Industrie Farmaceutiche Riunite Srl 37
Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl 37
Clinical Trial Overview of Top Institutes / Government 38
National Heart, Lung, and Blood Institute 38
Clinical Trial Overview of National Heart, Lung, and Blood Institute 38
Erasmus MC 39
Clinical Trial Overview of Erasmus MC 39
Assistance Publique - Hopitaux de Paris 40
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 40
Washington University School of Medicine 41
Clinical Trial Overview of Washington University School of Medicine 41
Charles University 42
Clinical Trial Overview of Charles University 42
University of Edinburgh 43
Clinical Trial Overview of University of Edinburgh 43
Asan Medical Center 44
Clinical Trial Overview of Asan Medical Center 44
Helsinki University Central Hospital 45
Clinical Trial Overview of Helsinki University Central Hospital 45
Aarhus University Hospital 46
Clinical Trial Overview of Aarhus University Hospital 46
Sahlgrenska University Hospital 47
Clinical Trial Overview of Sahlgrenska University Hospital 47
Five Key Clinical Profiles 48
Appendix 69
Abbreviations 69
Definitions 69
Research Methodology 70
Secondary Research 70
About GlobalData 71
Contact Us 71
Disclaimer 71
Source 71

List of Tables
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aortic Valve Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Aortic Valve Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Aortic Valve Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Aortic Valve Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Aortic Valve Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Aortic Valve Stenosis Therapeutics, Global, Suspended Clinical Trials, 2014* 23
Aortic Valve Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 23
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Aortic Valve Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 25
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Edwards Lifesciences Corporation, 2014* 30
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CryoLife, Inc., 2014* 31
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 32
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 33
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 34
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Direct Flow Medical, Inc., 2014* 35
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cerenis Therapeutics SA, 2014* 36
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by A. Menarini Industrie Farmaceutiche Riunite Srl, 2014* 37
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 38
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014* 39
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 40
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 41
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charles University, 2014* 42
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Edinburgh, 2014* 43
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 44
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Helsinki University Central Hospital, 2014* 45
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University Hospital, 2014* 46
Aortic Valve Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sahlgrenska University Hospital, 2014* 47

List of Figures
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Aortic Valve Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Aortic Valve Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Aortic Valve Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Aortic Valve Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Aortic Valve Stenosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Aortic Valve Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 24
Aortic Valve Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 25
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 26
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 27
Aortic Valve Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 70


Read the full report:
Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703947/Aortic-Valve-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
When shopping for a new data processing platform for IoT solutions, many development teams want to be able to test-drive options before making a choice. Yet when evaluating an IoT solution, it’s simply not feasible to do so at scale with physical devices. Building a sensor simulator is the next best choice; however, generating a realistic simulation at very high TPS with ease of configurability is a formidable challenge. When dealing with multiple application or transport protocols, you would be...
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, will introduce two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a...
Any startup has to have a clear go –to-market strategy from the beginning. Similarly, any data science project has to have a go to production strategy from its first days, so it could go beyond proof-of-concept. Machine learning and artificial intelligence in production would result in hundreds of training pipelines and machine learning models that are continuously revised by teams of data scientists and seamlessly connected with web applications for tenants and users.
IT organizations are moving to the cloud in hopes to approve efficiency, increase agility and save money. Migrating workloads might seem like a simple task, but what many businesses don’t realize is that application migration criteria differs across organizations, making it difficult for architects to arrive at an accurate TCO number. In his session at 21st Cloud Expo, Joe Kinsella, CTO of CloudHealth Technologies, will offer a systematic approach to understanding the TCO of a cloud application...
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Secure Channels, a cybersecurity firm, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Secure Channels, Inc. offers several products and solutions to its many clients, helping them protect critical data from being compromised and access to computer networks from the unauthorized. The company develops comprehensive data encryption security strategie...
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyer belt between the Software Factory and production stages. Artifacts are m...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Cloud resources, although available in abundance, are inherently volatile. For transactional computing, like ERP and most enterprise software, this is a challenge as transactional integrity and data fidelity is paramount – making it a challenge to create cloud native applications while relying on RDBMS. In his session at 21st Cloud Expo, Claus Jepsen, Chief Architect and Head of Innovation Labs at Unit4, will explore that in order to create distributed and scalable solutions ensuring high availa...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...